Completed PHASE3 INTERVENTIONAL 2-arm NCT00765817

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications

Sponsor: AstraZeneca

Conditions Type 2 Diabetes

Interventions exenatide placebo

Updated 7 times since 2017 Last updated: Oct 21, 2016 Started: Oct 31, 2008 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Eli Lilly and Company

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Athens, Greece , Atlanta, United States , Baton Rouge, United States , Bend, United States , Berkeley Heights, United States , Birmingham, United Kingdom , Boston, United States , Buena Park, United States , Carolina, Puerto Rico and 49 more locations